GlassScriptPhysician profile
Martha K Terris
NPI 1215948211
$5,695.52
in general payments reported to CMS, 2019-2025
35 companies · $1,221 in 2025
The $1,221 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $753 · 2020: $294 · 2021: $484 · 2022: $257 · 2023: $974 · 2024: $1,712 · 2025: $1,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,872 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,872.33 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,264.18 | 2023-2025 | Urolift, Barrigel |
| Coloplast Corp | $584.38 | 2021-2025 | Titan, Isiris Astent Removal Device |
| Boston Scientific Corporation | $430.41 | 2019-2024 | Solyx Sis System |
| Cook Medical LLC | $285.00 | 2019-2022 | |
| Procept Biorobotics Corporation | $257.57 | 2024-2025 | Aquabeam System |
| Janssen Biotech, INC. | $222.87 | 2019-2021 | |
| Astellas Pharma US INC | $217.32 | 2019-2023 | Xtandi |
| Merck Sharp & Dohme LLC | $206.55 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Ferring Pharmaceuticals INC. | $193.92 | 2024-2025 | Adstiladrin |
| Calyxo, INC. | $189.88 | 2025 | Cvac Aspiration System |
| Urogen Pharma, INC. | $183.62 | 2021-2024 | Jelmyto |
| Olympus America INC. | $172.43 | 2019-2024 | Itind System, Olympus |
| Neotract INC. | $144.11 | 2019-2020 | |
| Axonics, INC. | $118.97 | 2024 | Bulkamid, Axonics |
| Aroa Biosurgery Incorporated | $118.55 | 2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $113.57 | 2024-2025 | Erleada |
| Progenics Pharmaceuticals, INC. | $111.18 | 2025 | |
| Conmed Corporation | $109.82 | 2024 | Conmed Specimen Retrieval, Airseal, Abc Handpieces |
| Alnylam Pharmaceuticals INC. | $109.79 | 2024 | Oxlumo |
| Endo Pharmaceuticals INC. | $108.80 | 2023 | Xiaflex |
| Palette Life Sciences, INC. | $81.58 | 2020 | |
| Photocure INC | $55.33 | 2019-2025 | Cysview |
| Medtronic, INC. | $55.15 | 2024 | Interstim |
| Novartis Pharmaceuticals Corporation | $53.02 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $49.36 | 2021-2025 | Imfinzi |
| Intuitive Surgical, INC. | $40.00 | 2019 | |
| Baxter Healthcare | $39.53 | 2019-2021 | |
| Innovation Technologies INC | $36.32 | 2024 | Irrisept |
| Becton, Dickinson and Company | $30.72 | 2023 | Bard Urinary Drainage Bag |
| Bayer Healthcare Pharmaceuticals INC. | $21.06 | 2019 | |
| Ambu INC. | $20.13 | 2024 | |
| Travere Therapeutics, INC. | $20.11 | 2019-2021 | |
| Dornier Medtech America, INC | $19.53 | 2020 | |
| Covidien LP | $17.59 | 2019 | |
| Laborie Medical Technologies Corp. | $13.17 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Terris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.